FM regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} R-FM Regimen; Rituximab-Fludarabine-Mitoxantrone Regimen ==Overview== {{PAGENAME}} refers to a regimen consisting of rituxi...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[fludarabine]] and [[mitoxantrone]] used for the treatment of indolent [[non-Hodgkin's lymphoma]].<ref name="pmid15159414">{{cite journal| author=Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al.| title=Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 13 | pages= 2654-61 | pmid=15159414 | doi=10.1200/JCO.2004.07.170 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15159414 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[fludarabine]] and [[mitoxantrone]] used for the treatment of indolent [[non-Hodgkin's lymphoma]].<ref name="pmid15159414">{{cite journal| author=Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al.| title=Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 13 | pages= 2654-61 | pmid=15159414 | doi=10.1200/JCO.2004.07.170 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15159414 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|R|Rituximab}} | |||
{{chemo|F|Fludarabine}} | {{chemo|F|Fludarabine}} | ||
{{chemo|M|Mitoxantrone}} | {{chemo|M|Mitoxantrone}} | ||
==Indications== | ==Indications== | ||
*[[Non-Hodgkin's lymphoma]]<ref name="pmid15159414">{{cite journal| author=Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al.| title=Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 13 | pages= 2654-61 | pmid=15159414 | doi=10.1200/JCO.2004.07.170 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15159414 }} </ref> | *[[Non-Hodgkin's lymphoma]]<ref name="pmid15159414">{{cite journal| author=Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al.| title=Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 13 | pages= 2654-61 | pmid=15159414 | doi=10.1200/JCO.2004.07.170 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15159414 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Revision as of 19:32, 30 March 2015
|
WikiDoc Resources for FM regimen |
|
Articles |
|---|
|
Most recent articles on FM regimen |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FM regimen at Clinical Trials.gov Clinical Trials on FM regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FM regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FM regimen Discussion groups on FM regimen Patient Handouts on FM regimen Directions to Hospitals Treating FM regimen Risk calculators and risk factors for FM regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FM regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: R-FM Regimen; Rituximab-Fludarabine-Mitoxantrone Regimen
Overview
FM regimen refers to a regimen consisting of rituximab, fludarabine and mitoxantrone used for the treatment of indolent non-Hodgkin's lymphoma.[1]
Regimen
RRituximab
FFludarabine
MMitoxantrone
Indications
References
- ↑ 1.0 1.1 Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A; et al. (2004). "Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma". J Clin Oncol. 22 (13): 2654–61. doi:10.1200/JCO.2004.07.170. PMID 15159414.